The primary end point occurred in 136 patients ( 6.1 % ) treated with varespladib compared with 109 patients ( 5.1 % ) treated with placebo ( hazard ratio [ HR ] , 1.25 ; 95 % CI , 0.97-1 .61 ; log-rank P = .08 ) .